Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Prices IPO at $7.50 Per Share
Dynavax Prices IPO at $7.50 Per Share BERKELEY, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that it has priced its initial public offering of 6,000,000 shares of its common stock at $7.50 per share, below the estimated range.
View HTML
Toggle Summary Dynavax Announces Strategic Partnering Agreement With UCB Pharma for Development and Commercialization of Seasonal Allergy Products
Dynavax Announces Strategic Partnering Agreement With UCB Pharma for Development and Commercialization of Seasonal Allergy Products Berkeley, CA - February 5, 2004 - Dynavax Technologies Corporation announced today that it has entered into an agreement with UCB Pharma, the pharmaceuticals division
View HTML
Toggle Summary Dynavax Announces USPTO Declaration of Interference to Resolve Inventorship of ISS Intelectual Property
Dynavax Announces USPTO Declaration of Interference to Resolve Inventorship of ISS Intelectual Property Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA - December 18, 2003 - Dynavax Technologies Corporation, a privately
View HTML
Toggle Summary Dynavax Technologies and Berna Biotech Announce Collaboration
Dynavax Technologies and Berna Biotech Announce Collaboration Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berna Biotech Ltd Béatrice Keller Communications Manager communications@bernabiotech.com Phone +41 (0) 31 980 6522 Fax +41 (0)
View HTML
Toggle Summary Dynavax Technologies Corporation Files Registration Statement for Initial Public Offering
Dynavax Technologies Corporation Files Registration Statement for Initial Public Offering Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA - October 24, 2003 - Dynavax Technologies Corporation announced today that it has
View HTML
Toggle Summary Dynavax Names Daniel Levitt Vice President and Chief Medical Officer
Dynavax Names Daniel Levitt Vice President and Chief Medical Officer Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA - August 4, 2003 - Dynavax Technologies Corporation today announced the appointment of Daniel Levitt,
View HTML
Toggle Summary Dynavax Initiates Phase II Clinical Trial of ISS Vacine for Hepatitis B - Study Focuses on Single-Injection Approach
Dynavax Initiates Phase II Clinical Trial of ISS Vacine for Hepatitis B - Study Focuses on Single-Injection Approach Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA, September 4, 2002 - Dynavax Technologies, a privately
View HTML
Toggle Summary Dynavax Names William J. Dawson Vice President, Finance and Operations, and Chief Financial Officer
Dynavax Names William J. Dawson Vice President, Finance and Operations, and Chief Financial Officer Contact: Dynavax Technologies Corporation Dino Dina, M.D. President and CEO 510-848-5100 Berkeley, CA -- August 22, 2002 - Dynavax Technologies Corporation today announced the appointment of William
View HTML
Toggle Summary Dynavax Raises $34.8 Million In Private Equity Round Led By Care Capital
Dynavax Raises $34.8 Million In Private Equity Round Led By Care Capital Contact: Andrew Gengos Chief Financial Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA, April 25, 2002 - Dynavax Technologies, a privately held biopharmaceutical company, today announced that it had raised
View HTML
Toggle Summary Dynavax Names New Vice Presidents
Dynavax Names New Vice Presidents Contact: Dino Dina, M.D. President and CEO Dynavax Technologies Corporation (510) 848-5100 or (877) 848-5100 Berkeley, CA, December 6, 2000 - Dynavax Technologies Corporation today announced that it has named three new vice presidents, including Robert Lee Coffman,
View HTML